The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

184

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

June 15, 2030

Study Completion Date

December 30, 2030

Conditions

HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis

Interventions

DRUG

Trastuzumab Rezetecan

Trastuzumab Rezetecan 4.8mg/kg, IV, Day 1, Q3W

DRUG

Chemotherapy of Physician's Choice

Chemotherapy of Physician's Choice, including nab-paclitaxel, Eribulin, Capecitabine

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER